Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies

✍ Scribed by Malik E. Juweid; Cun-Hui Zhang; Rosalyn D. Blumenthal; Robert M. Sharkey; Robert Dunn; Douglas Dunlop; David M. Goldenberg

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 117 KB
• Volume: 80
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2749::aid-cncr55>3.0.co;2-8

✦ Synopsis

METHODS.

Ninety-nine patients who received 131 I-labeled anti-CEA MoAb for the Garden State Cancer Center, Center for Molecutreatment of CEA-producing cancers were assessed for platelet and white blood lar Medicine and Immunology, Belleville, New cell toxicity based on the common Radiation Therapy Oncology Group criteria. Jersey.

Multivariate regression analysis was used to identify the statistically significant factors affecting toxicity among the following variables: red marrow dose, baseline platelet and white blood cell counts, bone and/or marrow metastases, prior chemotherapy or radiotherapy, timing of prior chemotherapy or radiotherapy in relationship to RAIT, type and number of prior chemotherapeutic regimens, age, sex, antibody form, and cancer type.

RESULTS AND CONCLUSIONS. Red marrow dose, baseline platelet or white blood

Presented at the Sixth Conference on Radioimcell counts, multiple bone and/or marrow metastases, and chemotherapy 3-6 munodetection and Radioimmunotherapy of months before RAIT were the only four significant factors affecting hematologic Cancer, Princeton, New Jersey, October 10-12, toxicity according to multivariate analysis. The identification of bone and/or mar-1996.

row metastases and recent chemotherapy as significant factors for hematologic Supported in part by USPHS Outstanding Investoxicity could be important in the design of future clinical trials. Cancer tigator grant CA39841 (D.